Press release
Rheumatoid Arthritis Treatment Market Globally Expected to Drive Growth through 2024
Plethora of research work to introduce effective treatment therapies in the global rheumatoid arthritis treatment marketIntroduction of newer therapies are expected to fuel growth of rheumatoid arthritis treatment market in developed nations. Emerging economies are late adapters to new technologies and therapies, thus are potential markets for brands not yet marketed in these countries. The Chinese FDA recently approved Xeljanz for RZ treatment (2017). The product is awaiting approval from the EU. Among the Asian countries, India, China, Pakistan, and Bangladesh had major prevailing rheumatoid arthritis patients as per WHO–ILAR COPCORD (International League of Associations for Rheumatology) (Community Oriented Program for Control of Rheumatic Diseases) studies (2015). Some of the products in pipeline include:
--Antibodies that target collagen II, an important protein in joint cartilage (Researchers at the --Department of Immunology, Genetics and Pathology, Uppsala University, Sweden)
--Stem cell I.V. therapy developed by Mesoblast Ltd. to treat RA patients unresponsive to TNF drugs (phase 2 trials)
To understand Research Methodology, please click: https://www.coherentmarketinsights.com/insight/request-sample/166
More of such developments by the market players will be a significant contributor towards the growth of global rheumatoid arthritis treatment industry.
NSAIDs and corticosteroid are also the first-line fast acting therapeutic drugs. Acetylsalicylate, naproxen, ibuprofen, etodolac, and diclofenac are the NSAIDs usually prescribed as first-line drugs for RA. These drugs reduce inflammation, and pain. Corticosteroid medications are given either orally or parenterally to reduce inflammation and restore joint mobility and function. These class of drugs are more potent than NSAIDs and therefore usually preferred a first line therapy by prescribers. The global rheumatoid arthritis treatment industry is expected to be driven considerably in near future by DMARDs that form second line slow-acting therapeutic drugs. Longer therapeutic regimen with these drugs increases cost of therapy and also promote remission of joint destruction and deformity. Methotrexate is the most commonly prescribed second line drug for RA and hence, occupies major share in the respective segment of global rheumatoid arthritis treatment market. Tofacitinib (Xeljanz) is the most potential FDA approved Janus kinase (JAK) inhibitor available in the global market of rheumatoid arthritis treatment.
FDA approved biologic drugs include rituximab (Rituxan, MabThera), abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), anakinra (Kineret), infliximab (Remicade), golimumab (Simponi), and tocilizumab (Actemra). Besides these approved drugs, biosimilars in pipeline would fuel the rheumatoid arthritis treatment market growth in near future.
Key statistics pertaining to the global rheumatoid arthritis treatment market:
Over time, there is damage to cartilage and mobility function of the affected joint in rheumatoid arthritis patient.
--Affects nearly 1.3 million U.S. population (RheumatoidArthritis.org)
--Most common in the age group of 30-60 years
--Global prevalence varies in the range of 0.3% to 1% (World Health Organization)
--Average annual cost of treatment may go up to US $20,000 (RheumatoidArthritis.org)
--According to the Arthritis Foundation, people with RA loose more workdays compared to those affected by any other medical condition
--According to a Harvard University study published in the Journal of Global Health (2017), prevalence of rheumatoid arthritis in Southeast Asian countries was 0.4%, 0.42 in western Pacific region, and 0.37% in eastern Mediterranean countries
Have a doubt? Speak to our analyst now! https://www.coherentmarketinsights.com/insight/talk-to-analyst/166
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the most. Treatments available for rheumatoid arthritis aids to relive symptoms and improve the joint function. A comprehensive treatment for RA usually involves integration of patient education, exercise, medications, and surgery (occasionally). The rheumatoid arthritis treatment market can be analyzed based on the drug type, as follows:
--Biological drugs
--Monoclonal antibodies
--Non-Biologicals
--Non-steroidal Anti-inflammatory Drugs (NSAIDs)
--Corticosteroids
--Analgesics
--Disease-modifying anti-rheumatic drugs (DMARDs)
--IL-6 inhibitors
--TNF inhibitors
Some of the major players in the global rheumatoid arthritis treatment market are Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rheumatoid Arthritis Treatment Market Globally Expected to Drive Growth through 2024 here
News-ID: 997719 • Views: …
More Releases from Pharmaceutical

Pharmaceutical Market Report 2018 Companies included CCM Pharmaceuticals, Pharma …
We have recently published this report and it is available for immediate purchase. For inquiry Email us on: jasonsmith@marketreportscompany.com *********
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for the year 2018 to 2025, etc. The report also provides…

Equine Healthcare Market Global Industry Insights, Trends, 2026
Equine Healthcare refers to the activities and practices aimed for the maintenance of horses. Equine healthcare offers the veterinary services intended for treating horses to enhance their quality of life, develop quality animal food and increase lifespan. The total equine population is directly proportional to the quality of equine healthcare. Equine healthcare includes a number of activities including diagnosis, therapies and supplements for maintaining internal health of horses. The…

Novel Drug Delivery System (NDDS) Market - Global Industry Insights
Novel Drug Delivery System (NDDS) refers to the formulations, systems to transport pharmaceutical compound in the body, and approaches needed to achieve the desired therapeutic effect. The side effects and slow processing of conventional drug therapy are contributing to the emergence of novel drug delivery system’s concept. Novel ideas based on interdisciplinary approaches controlling the pharmacodynamics, immunogenicity, pharmacokinetics, bio-recognition, and efficiency of drugs were generated. This new system helps in…

The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 a …
The Global Anti-suicide Drugs Market was valued at US$ 3,318.3 million in 2015 and is projected to expand at a CAGR of 4.2% during the forecast period (2016-2024), as highlighted in a new report published by Coherent Market Insights. Introduction of novel approved drugs, expected to be commercialized post-2020, intended for treatment of suicidal ideation would be a major breakthrough for the global anti-suicide drugs market.
Until recently, suicidal ideation has…
More Releases for Arthritis
Canine Arthritis Treatment Market to 2028 |Dechra Pharmaceuticals PLC, Canine Ar …
Market Research Hub (MRH) has carefully analyzed this research study titled Canine Arthritis Treatment Market: Asia Pacific Excluding Japan to Register the Fastest Growth During the Forecast Period: Global Industry Analysis (2013-2017) and Opportunity Assessment (2018-2028), which is available on its online portal. The aim of this assessment is to highlight the various projections expected to occur in the global market for Canine Arthritis Treatment. Readers can gain knowledge related…
Arthritis Consumer Experts launches JointHealth™ Education Advanced Therapies …
June 21, 2018
For Immediate Release
ACE launches JointHealth™ Education Advanced Therapies
North America’s first course designed to educate arthritis patients introduces new lesson on advanced therapies for inflammatory arthritis
(VANCOUVER) — Arthritis Consumer Experts (ACE) announced the launch of its newest on-line patient education course: JointHealth™ Education Advanced Therapies for Inflammatory Arthritis. This three-lesson course is designed to help patients living with inflammatory arthritis identify when the appropriate time to transition from conventional…
Rheumatoid Arthritis Drug Market Rheumatoid Arthritis Clinical Pipeline Report 2 …
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis
Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers
Classification of Rheumatoid Arthritis Drugs
3.1…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
Rheumatoid Arthritis Treatment Market
Rheumatoid arthritis (RA) is the most common autoimmune arthritis affecting more than 1.3 million U.S. citizens (American College of Rheumatology). More surprising is to know that around 75% of this affected population is women. Affecting the joints at any age, rheumatoid arthritis needs to be addressed early to avoid expensive joint replacement surgery. While it can affect any joint, small joints in hand and feet tend to be affected the…
Worldwide Arthritis - EpiCast Report: Rheumatoid Arthritis - Epidemiology Foreca …
"EpiCast Report: Rheumatoid Arthritis - Epidemiology Forecast to 2025" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.
Description-
** Summary
Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the bodys immune system attacks the lining of the joints, known as…